Recombinant norovirus-specific scFv inhibit virus-like particle binding to cellular ligands
© Ettayebi and Hardy. 2008
Received: 30 November 2007
Accepted: 31 January 2008
Published: 31 January 2008
Noroviruses cause epidemic outbreaks of gastrointestinal illness in all age-groups. The rapid onset and ease of person-to-person transmission suggest that inhibitors of the initial steps of virus binding to susceptible cells have value in limiting spread and outbreak persistence. We previously generated a monoclonal antibody (mAb) 54.6 that blocks binding of recombinant norovirus-like particles (VLP) to Caco-2 intestinal cells and inhibits VLP-mediated hemagglutination. In this study, we engineered the antigen binding domains of mAb 54.6 into a single chain variable fragment (scFv) and tested whether these scFv could function as cell binding inhibitors, similar to the parent mAb.
The scFv54.6 construct was engineered to encode the light (VL) and heavy (VH) variable domains of mAb 54.6 separated by a flexible peptide linker, and this recombinant protein was expressed in Pichia pastoris. Purified scFv54.6 recognized native VLPs by immunoblot, inhibited VLP-mediated hemagglutination, and blocked VLP binding to H carbohydrate antigen expressed on the surface of a CHO cell line stably transfected to express α 1,2-fucosyltransferase.
scFv54.6 retained the functional properties of the parent mAb with respect to inhibiting norovirus particle interactions with cells. With further engineering into a form deliverable to the gut mucosa, norovirus neutralizing antibodies represent a prophylactic strategy that would be valuable in outbreak settings.
Noroviruses are non-enveloped positive strand RNA viruses that cause foodborne illness worldwide . They are classified as NIAID Category B priority pathogens because they are easily transmitted person-to-person and can cause persistent epidemics. Outbreaks generally occur in semi-closed community settings including day care centers, retirement facilities and nursing homes, hospitals, schools, and military training and operations facilities. Large outbreaks on commercial cruise-liners have been well publicized, and such outbreaks illustrate the rapid onset epidemic potential of noroviruses and a need for intervention measures that do not depend on pre-existing immunity. Recent data suggest the number of outbreaks attributable to noroviruses may be increasing .
The norovirus genome is a 7.7 kilobase RNA comprised of three open reading frames (ORF) [reviewed in ]. ORF1 codes for the nonstructural proteins that are processed co- and post-translationally by a single viral protease. ORF2 and ORF3 encode structural proteins VP1 and VP2, respectively, and form the icosahedral capsid. Ninety dimers of VP1 assemble into virus-like particles (VLPs) when expressed in insect cells infected with a recombinant baculovirus . VP1 folds into two major domains termed the shell (S) and protruding (P) domains [5, 6]. The S domain consists of the N -terminal 280 amino acids and forms the icosahedron. The P domain is divided into sub-domains P1 and P2 that participate in dimeric contacts that increase the stability of the capsid. The P2 domain is an insertion in the P1 domain and contains a hypervariable region implicated in receptor binding and immune reactivity, as well as in interactions with histoblood group antigens associated with susceptibility to norovirus infections [7–11].
Therapeutic antibodies have been used successfully in treatment regimens for diseases including cancer and rheumatoid arthritis, for transplant rejection, and against respiratory syncytial virus infections in children [reviewed in ]. Technological advances that include humanization to avoid undesirable immunogenicity, and improvements in stability and pharmacokinetics are strategies employed to improve the clinical utility of antibodies. Foremost among such strategies is the reduction of antigen binding domains to minimal fragments that retain reactivity with the targeted antigens . Single chain variable fragments (scFv) are ~27 kDa recombinant proteins that consist of the light (VL) and heavy (VH) chain variable regions of a monoclonal antibody (mAb) expressed in a single construct where they are separated by a flexible peptide linker . Intramolecular folding of the recombinant protein results in reconstitution of the antigen binding domain. These small proteins are relatively easily produced in high yield in recombinant bacterial or yeast expression systems [15–17]. Further manipulation and expression strategies have yielded forms of the scFv monomer where valency is increased by assembly of multimeric forms termed diabodies, triabodies and tetrabodies . These multimers have been shown to be more stable and can be engineered to recognize more than one antigenic target [18, 19].
We generated mAb to norovirus VLPs to characterize domains of VP1 that function in virus binding to cellular receptors . One mAb (mAb 54.6) to the genogroup I reference strain Norwalk (NV) blocks binding of recombinant VLPs to CaCo-2 intestinal cells and inhibits VLP-mediated hemagglutination. In the current study, we engineered sequences encoding mAb 54.6 into an scFv to determine whether functional activity was retained in the isolated antigen binding domain. The data presented show the scFv from mAb 54.6 (scFv54.6) was expressed successfully in Pichia pastoris and retained the antigen binding and functional activity of the parent mAb. Engineered antibody fragments that block norovirus binding to cells have potential as an on-site prophylactic strategy to prevent virus spread and contain epidemics.
VL and VH domains of mAb 54.6 and design of scFv54.6
The domain organization of the 245 amino acid scFv54.6 consists of the VL domain at the N terminus separated from the VH domain at the C terminus by a peptide linker comprised of the sequence GGKGSGGKGTGGKGSGGKGS (Figure 1). The linker composition is a modification of the peptide linker previously described . C-terminal myc and histidine tags are expressed in frame with scFv54.6 to allow detection of recombinant protein by immunoblot and for downstream purification procedures.
Production of scFv54.6 in P. pastoris and reactivity with rNV VP1
scFv54.6 blocks rNV VLP-mediated hemagglutination
scFv54.6 blocks binding of rNV VLPs to CHO-FTBKE cells
Immunity to noroviruses is complex and the correlates of protection from re-infection are unclear. Short-term immunity can be induced by prior infection, but long-lasting immunity apparently is more difficult to achieve. Gastroenteritis caused by norovirus generally is a self-limiting disease. However, the ease in which noroviruses are transferred by person-to-person spread suggest inhibitors designed to interfere with the initial steps of virus infection could reduce the duration of illness, shedding of infectious virus, and the number of susceptible individuals in a population. This issue is particularly relevant in semi-closed communities including nursing homes and daycare centers, where age may affect the efficacy of vaccines. We envision that inhibitors will be easily administered on-site as necessary and will by design, be independent of an adaptive immune response.
P. pastoris was chosen for scFv54.6 expression because of reported high protein yield, low levels of glycosylation, simplicity of the culture medium and protein solubility. Numerous scFvs have been produced in P. pastoris with variable yields ranging from 0.4 to 20 mg/L [26, 32, 33]. We have shown that scFv54.6 expressed in P. pastoris at yields of ~1.0 mg/L retain the inhibitory functions of the parent mAb, suggesting humanized derivatives of these fragments could prove useful for development of anti-norovirus prophylactics.
Antibodies have received significant interest as biopharmaceuticals. At least 18 mAb are in use in humans and > 100 are in clinical trials as therapeutics for treatment of cancer and chronic inflammatory diseases, and for prevention of transplant organ rejection . Likewise, engineered smaller domains consisting of the functional antigen binding domains are viable alternatives to the costs associated with humanization and production of mAb in mammalian cell culture systems . Monovalent scFv are easily produced in high yield in recombinant bacterial or yeast expression systems, and when secreted into the medium, are readily purified to homogeneity by scalable purification procedures. scFv also can be designed to be bispecific, or engineered to preferentially form multimers including diabodies, triabodies, and tetrabodies that increase valency . These multivalent properties with consequent increased avidity are particularly relevant for prophylaxis of viral diseases because, similar to other cellular receptor-ligand interactions, viral attachment proteins engage multiple copies of receptors on the cell surface.
Several examples of antibody fragments capable of neutralizing virus infection both in vitro and in vivo have been reported. For example, fragments selected from a human scFv library for reactivity with the West Nile virus envelope protein protected mice against lethal virus challenge when administered both prior to or shortly after infection . Recombinant virus-specific scFv efficiently neutralized human papillomavirus infection in culture . Affinity-selected scFv against hepatitis B virus also neutralized infection in vitro , and purified scFv that recognize intercellular adhesion molecule ICAM-1 effectively blocked transmission of HIV across an epithelial cell monolayer both in vitro and in a small animal model . Together, these data illustrate the utility of scFv as a viable way to provide passive immunity to viral infections.
Our studies were approached with the idea that engineered antibody fragments could provide a rapidly deliverable substance for protection against norovirus infection where the potential for epidemics is heightened in semi-closed community settings. However, successful delivery of soluble proteins, including scFv, to the gut is unlikely because of potential instability from exposure to gut proteases. Recently, pathogen-specific scFv expressed on the surface of probiotic lactobacilli provided protection in small animal models of enteric viral infection . This or a similar system that is amenable to oral administration could provide scaffolding for stable presentation of norovirus neutralizing scFv to the gut.
The antigenic specificity in the norovirus capsid lies primarily in the hypervariable P2 domain of VP1, and ideally, antibody fragments would be reactive with multiple strains. Genogroup II.4 strains currently are the predominant strains circulating worldwide, but others also have been reported [2, 39–42]. In the absence of broadly cross-reactive antibodies, the ability to manipulate scFv fragments into bispecific molecules suggests these neutralizing fragments can be engineered to cover a combination of antigenic types within a single delivery system. Construction of such bispecific fragments is underway.
Material and methods
Cloning of variable domain genes
Degenerate oligonucleotides for PCR amplification of VL and VH of mAb 54.6
5'- GAC HGA TGG GGS TGT YGT GCT AGC TGN RGA GAC DGT GA -3'
5'- GGA TAC AGT TGG TGC AGT CGA CTT ACG TTT KAT TTC CAR CTT -3'
5'- GGG GAT ATC CAC CAT GGA GAC AGA CAC ACT CCT GCT AT -3'
5'- GGG GAT ATC CAC CAT GGA TTT TCA AGT GCA GAT TTT CAG -3'
5'- GGG GAT ATC CAC CAT GGA GWC ACA KWC TCA GGT CTT TRT A -3'
5'- GGG GAT ATC CAC CAT GKC CCC WRC TCA GYT YCT KGT -3'
5'- GGG GAT ATC CAC CAT GAA GTT GCC TGT TAG GCT GTT G -3'
5'- GGG GAT ATC CAC CAT GGR ATG SAG CTG KGT MAT SCT CTT -3'
5'- GGG GAT ATC CAC CAT GRA CTT CGG GYT GAG CTK GGT TTT -3'
5'- GGG GAT ATC CAC CAT GGC TGT CTT GGG GCT GCT CTT CT -3'
5'- GGG GAT ATC CAC CAT GAT RGT GTT RAG TCT TYT GTR CCT G -3'
Primers for cloning VL and VH of mAb 54.6 into P. pastoris expression vector pPICZαA
5'- CAC GAA TTC GAC ATC TTG CTG ACT CAG TCT CCA GCC -3'
5'- CTA CGG TAC CCT TAC CTC CAG ATC CCT TAC CTC CTT TGA TTT CCA ACT TGG TGC C -3'
5'- CAC GGG TAC CGG AGG TAA GGG ATC TGG AGG TAA GGG ATC TGA AGT GAA ATT GGT GGA GTC -3'
5'- GGC ACT CTA GAG AGG AGA CAG TGA GAG TGG TGC C -3'
Transformation of P. pastoris X33 and selection of recombinants
P. pastoris strain X33 was transformed with 10 μg of Pme I-linearized pPICZαA-scFv54.6 following the Easyselect Pichia expression protocol (Invitrogen). In brief, electro-competent cells were prepared from 200 ml of YPD medium inoculated with a fresh culture of P. pastoris X33 and incubated at 29°C, shaking at 250 rpm until the OD600 nm reached 1.3. The cells then were harvested by centrifugation for five minutes at 1,500 × g, washed twice with sterile ice-cold water and once with 10 ml of ice-cold 1 M sorbitol, and then suspended in 0.5 ml of 1 M sorbitol. Electroporation was conducted by mixing 80 μl of this cell suspension with 10 μg of linearized pPICZαA-scFv54.6 in a 0.2-cm cuvette. The cells were pulsed with 1.5 kV at a resistance setting of 129 ohms using a BTX ECM 630 electroporator. One ml of 1.0 M sorbitol was immediately added to the pulsed cells which then were transferred to a 15 ml tube and incubated for two hours at 29°C. Cells were plated onto YPD agar supplemented with 1.0 M sorbitol and containing 100 μg/ml of zeocin. Colonies were screened for multi-copy recombinants by patching onto YPD agar plates containing concentrations of zeocin ranging from 100 to 2,000 μg/ml. Recombinants selected on 2,000 μg/ml zeocin were screened for Met+ phenotype by streaking onto minimal methanol agar medium and inserts were confirmed by PCR.
scFv expression and purification
scFv54.6 expression was conducted by growing recombinants in 50 ml buffered complex glycerol medium (BGMY, pH 6.0) for 18 hrs at 29°C. Cells cultured to log phase were harvested by centrifugation at 1,500 × g, diluted to an OD600 nm of 1.0 in buffered complex methanol medium (BMMY, pH 6.0) to induce expression, and then incubated for 72 hrs at 25°C in a shaking incubator at 250 rpm. At each 24 hour time point, 100% methanol was added to a final concentration of 1.0%. Casamino acids were added to BMMY to a final concentration of 1.0% to reduce proteolysis. One ml samples were taken at selected time points and supernatants were analyzed for scFv54.6 expression by SDS-PAGE and immunoblotting using anti-c-myc (Clontech) as the primary antibody.
The pre-cleared supernatant from induced cultures was precipitated by addition of ammonium sulfate to 45% saturation and incubated overnight at 4°C. Proteins were harvested by centrifugation for 25 minutes at 6,700 × g and then dialyzed against sodium phosphate saline buffer (50 mM monobasic sodium phosphate, 150 mM NaCl, pH 7.4). The dialysate was diluted with an equal volume of Ni-NTA buffer (50 mM monobasic sodium phosphate, 300 mM NaCl, pH 8.0) containing 25 mM imidazole and then incubated with Ni-NTA beads for 20 minutes at 4°C with end-over-end rotation. Beads were collected by centrifugation for two minutes at 800 × g and then washed five times with wash buffer (50 mM monobasic sodium phosphate, 300 mM NaCl, 20 mM imidazole, pH 8.0). His-tagged proteins were eluted with Ni-NTA buffer containing 250 mM imidazole, dialyzed against sodium phosphate buffer, pH 6.5, and concentrated by ultrafiltration through a Centricon Plus-20 column (Millipore).
Hemagglutination inhibition assay (HI)
The HI assay was performed as described previously . In brief, 50 μl serial dilutions of purified scFv54.6 or mAb 54.6 in sterile PBS-H (0.01 M sodium phosphate, 0.15 M sodium chloride, pH 5.5) were added to the wells of a vinyl flexible V-bottom 96-well plate (Costar), followed by addition of 50 μl of a 0.5 % suspension of type O red blood cells. Ten μl of VLPs (5 ng/ml in PBS-H) or PBS-H were added to the appropriate wells indicated in the figure legend. The plate was gently agitated and incubated for two hours at 4°C.
Construction of CHO-FTBKE cells and VLP blocking assays
A stable Chinese Hamster Ovary (CHO) cell line that expresses α 1,2-fucosyltransferase (α 1,2-FT) was constructed as previously described . The rat FTB gene encoding α 1,2-FT was amplified by RT-PCR from total RNA isolated from rat colon using oligonucleotides FTB-F (5' CAAGGATCCATGGCCAGCGCCCAGGTT-3') and FTB-R (5' CACCTCGAGTTAGTGCTTAAGGAGTGGGGAC-3'). The PCR amplicon was cloned in BamHI and XhoI sites of pcDNA3.1/Myc-His(+)A vector (Clontech). CHO-K1 cells were transfected with the FTB cDNA and stably maintained in RPMI containing 0.4 mg/ml G418. Expression of α 1,2-FT was confirmed by binding of FITC-conjugated UEA-lectin as previously described .
The ability of scFv54.6 to block binding of VLPs to cells was measured by flow cytometry using R-Phycoerythrin (PE)-conjugated anti-mouse IgG (Jackson Immunoresearch Laboratories). Binding assays were performed as described previously . Briefly, 990 ng of VLPs diluted in PBS (pH 6.7) containing 0.1% gelatin were incubated for two hours at 4°C in the presence or in the absence of scFv54.6 (5 μg/ml) or control IgG Fab fragment (Jackson Immunoresearch Labs). The reactions were mixed with 2 × 105 CHO-FTBKE cells and incubated for another two hours. Cells were washed and VLP binding was detected by incubation for one hour with anti-rNV mAb 72.1  followed by a 45 minute incubation with PE-conjugated goat anti-mouse antibody at a final concentration of 2.0 μg/ml. MAb 72.1 recognizes rNV particles but is different from mAb 54.6, as their VL and VH sequences are not identical (unpublished data). Fluorescent cells were counted on a FACSCalibur (Becton Dickinson) and the data were analyzed with CellQuest Pro software (version 5.2.1; BD Biosciences).
This work was sponsored in part by a subcontract to MEH from LigoCyte Pharmaceuticals, Bozeman, MT, through US Army Medical Research and Materiel Command Contract Number DAM17-01-C-0040. The views, opinions and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy or decision, unless so designated by other documentation. Additional support was provided by the Montana Ag Experiment Station and PHS grant P20 RR020185.
- Green KY: Human caliciviruses. Fields Virology (Edited by: Knipe DM and Howley PM). Philadelphia, PA, Lippincott Williams & Wilkins 2001, 841–874.
- Widdowson MA, Monroe SS, Glass RI: Are noroviruses emerging? Emerg Infect Dis 2005, 11:735–737.PubMed
- Hardy ME: Norovirus protein structure and function. FEMS Microbiol Lett 2005, 253:1–8.View ArticlePubMed
- Jiang X, Wang M, Graham DY, Estes MK: Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 1992, 66:6527–6532.PubMed
- Prasad BV, Rothnagel R, Jiang X, Estes MK: Three-dimensional structure of baculovirus-expressed Norwalk virus capsids. J Virol 1994, 68:5117–5125.PubMed
- Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK: X-ray crystallographic structure of the Norwalk virus capsid. Science 1999, 286:287–290.View ArticlePubMed
- Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS: Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol 2002, 76:12335–12343.View ArticlePubMed
- Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, Stewart P, LePendu J, Baric R: Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003, 9:548–553.View ArticlePubMed
- Hutson AM, Atmar RL, Graham DY, Estes MK: Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis 2002, 185:1335–1337.View ArticlePubMed
- Hutson AM, Atmar RL, Marcus DM, Estes MK: Norwalk virus-like particle hemagglutination by binding to h histo- blood group antigens. J Virol 2003, 77:405–415.View ArticlePubMed
- Hutson AM, Atmar RL, Estes MK: Norovirus disease: changing epidemiology and host susceptibility factors. Trends Microbiol 2004, 12:279–287.View ArticlePubMed
- Brekke OH, Sandlie I: Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003, 2:52–62.View ArticlePubMed
- Holliger P, Hudson PJ: Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005, 23:1126–1136.View ArticlePubMed
- Huston JS, McCartney J, Tai MS, Mottola-Hartshorn C, Jin D, Warren F, Keck P, Oppermann H: Medical applications of single-chain antibodies. Int Rev Immunol 1993, 10:195–217.View ArticlePubMed
- Miller KD, Weaver-Feldhaus J, Gray SA, Siegel RW, Feldhaus MJ: Production, purification, and characterization of human scFv antibodies expressed in Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli. Protein Expr Purif 2005, 42:255–267.View ArticlePubMed
- Lamberski JA, Thompson NE, Burgess RR: Expression and purification of a single-chain variable fragment antibody derived from a polyol-responsive monoclonal antibody. Protein Expr Purif 2006, 47:82–92.View ArticlePubMed
- D'Alatri L, Di Massimo AM, Anastasi AM, Pacilli A, Novelli S, Saccinto MP, De Santis R, Mele A, Parente D: Production and characterisation of a recombinant single-chain anti ErbB2-clavin immunotoxin. Anticancer Res 1998, 18:3369–3373.PubMed
- Holliger P, Winter G: Engineering bispecific antibodies. Curr Opin Biotechnol 1993, 4:446–449.View ArticlePubMed
- Holliger P, Prospero T, Winter G: "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 1993, 90:6444–6448.View ArticlePubMed
- Lochridge VP, Jutila KL, Graff JW, Hardy ME: Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions. J Gen Virol 2005, 86:2799–2806.View ArticlePubMed
- Pech M, Hochtl J, Schnell H, Zachau HG: Differences between germ-line and rearranged immunoglobulin V kappa coding sequences suggest a localized mutation mechanism. Nature 1981, 291:668–670.View ArticlePubMed
- Williams GS, Martinez A, Montalbano A, Tang A, Mauhar A, Ogwaro KM, Merz D, Chevillard C, Riblet R, Feeney AJ: Unequal VH gene rearrangement frequency within the large VH7183 gene family is not due to recombination signal sequence variation, and mapping of the genes shows a bias of rearrangement based on chromosomal location. J Immunol 2001, 167:257–263.PubMed
- Bellon B, Manheimer-Lory A, Monestier M, Moran T, Dimitriu-Bona A, Alt F, Bona C: High frequency of autoantibodies bearing cross-reactive idiotopes among hybridomas using VH7183 genes prepared from normal and autoimmune murine strains. J Clin Invest 1987, 79:1044–1053.View ArticlePubMed
- Clarke SH, Huppi K, Ruezinsky D, Staudt L, Gerhard W, Weigert M: Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin. J Exp Med 1985, 161:687–704.View ArticlePubMed
- Hartman AB, Rudikoff S: VH genes encoding the immune response to beta-(1,6)-galactan: somatic mutation in IgM molecules. EMBO J 1984, 3:3023–3030.PubMed
- Cunha AE, Clemente JJ, Gomes R, Pinto F, Thomaz M, Miranda S, Pinto R, Moosmayer D, Donner P, Carrondo MJ: Methanol induction optimization for scFv antibody fragment production in Pichia pastoris. Biotechnol Bioeng 2004, 86:458–467.View ArticlePubMed
- Tschopp JF, Brust PF, Cregg JM, Stillman CA, Gingeras TR: Expression of the lacZ gene from two methanol-regulated promoters in Pichia pastoris. Nucleic Acids Res 1987, 15:3859–3876.View ArticlePubMed
- Scorer CA, Buckholz RG, Clare JJ, Romanos MA: The intracellular production and secretion of HIV-1 envelope protein in the methylotrophic yeast Pichia pastoris. Gene 1993, 136:111–119.View ArticlePubMed
- Xie YF, Chen H, Huang BR: Expression, purification and characterization of human IFN-lambda1 in Pichia pastoris. J Biotechnol 2007, 129:472–480.View ArticlePubMed
- Huang P, Farkas T, Zhong W, Tan M, Thornton S, Morrow AL, Jiang X: Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol 2005, 79:6714–6722.View ArticlePubMed
- Marionneau S, Ruvoen N, Moullac-Vaidye B, Clement M, Cailleau-Thomas A, Ruiz-Palacois G, Huang P, Jiang X, Le Pendu J: Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 2002, 122:1967–1977.View ArticlePubMed
- Emberson LM, Trivett AJ, Blower PJ, Nicholls PJ: Expression of an anti-CD33 single-chain antibody by Pichia pastoris. J Immunol Methods 2005, 305:135–151.View ArticlePubMed
- Hu S, Li L, Qiao J, Guo Y, Cheng L, Liu J: Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia pastoris. Protein Expr Purif 2006, 47:249–257.View ArticlePubMed
- Gould LH, Sui J, Foellmer H, Oliphant T, Wang T, Ledizet M, Murakami A, Noonan K, Lambeth C, Kar K, Anderson JF, de Silva AM, Diamond MS, Koski RA, Marasco WA, Fikrig E: Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol 2005, 79:14606–14613.View ArticlePubMed
- Culp TD, Spatz CM, Reed CA, Christensen ND: Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 2007, 361:435–446.View ArticlePubMed
- Park SG, Jung YJ, Lee YY, Yang CM, Kim IJ, Chung JH, Kim IS, Lee YJ, Park SJ, Lee JN, Seo SK, Park YH, Choi IH: Improvement of neutralizing activity of human scFv antibodies against hepatitis B virus binding using CDR3 V(H) mutant library. Viral Immunol 2006, 19:115–123.View ArticlePubMed
- Chancey CJ, Khanna KV, Seegers JF, Zhang GW, Hildreth J, Langan A, Markham RB: Lactobacilli-expressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cell-associated HIV-1 transmission across a cervical epithelial monolayer. J Immunol 2006, 176:5627–5636.PubMed
- Pant N, Hultberg A, Zhao Y, Svensson L, Pan-Hammarstrom Q, Johansen K, Pouwels PH, Ruggeri FM, Hermans P, Frenken L, Boren T, Marcotte H, Hammarstrom L: Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis 2006, 194:1580–1588.View ArticlePubMed
- Fankhauser RL, Monroe SS, Noel JS, Humphrey CD, Bresee JS, Parashar UD, Ando T, Glass RI: Epidemiologic and molecular trends of "Norwalk-like viruses" associated with outbreaks of gastroenteritis in the United States. J Infect Dis 2002, 186:1–7.View ArticlePubMed
- Blanton LH, Adams SM, Beard RS, Wei G, Bulens SN, Widdowson MA, Glass RI, Monroe SS: Molecular and epidemiologic trends of caliciviruses associated with outbreaks of acute gastroenteritis in the United States, 2000–2004. J Infect Dis 2006, 193:413–421.View ArticlePubMed
- Vinje J, Koopmans MP: Molecular detection and epidemiology of small round-structured viruses in outbreaks of gastroenteritis in the Netherlands. J Infect Dis 1996, 174:610–615.PubMed
- Siebenga JJ, Vennema H, Duizer E, Koopmans MP: Gastroenteritis caused by norovirus GGII.4, The Netherlands, 1994–2005. Emerg Infect Dis 2007, 13:144–146.PubMed
- Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C: Sequences of protenis of immunolgical interest. National Technical Information Services (NTIS) 1991., NIH Publication NO. 91–3242:
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.